Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Kellie Ryan, MPH
Advertisement
Articles by Kellie Ryan, MPH
Advertisement
Latest Updated Articles
Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLLJanuary 10th 2020
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
5